‘Velcade’ generic market of KRW 20 billion will open next year

Published: 2015-11-19 15:44:34

Updated: 2015-11-19 15:44:34

Boryung Pharm will enter competition of Velcade(bortezomib, Janssen Korea) generics, a blockbuster multiple myeloma treatment.

According to the Ministry of Food and Drug Safety and the industry concerned on the 17^th, Boryung Pharm acquired domestic approval of ‘Velkin Inj 3.5mg.’

Indications of Velkin Inj are multiple myeloma and mantle cell lymphoma, which is attempted to be treated more tha...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.